Potentiation of oncolytic virotherapy with armed shRNA

Cancer Biology and Therapy

Volumn 8, Issue 1, 2009, Pages 92-93

  Guo, Wei ^a   Fang, Bingliang ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenovirus; Apoptosis; Htert; Oncolytic virotherapy; shRNA; Telomerase; Tumor

Indexed keywords

ONCOLYTIC ADENOVIRUS; ONCOLYTIC VIRUS; ONYX 015; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ZD55 ENHANCED GREEN FLUORESCENT PROTEIN; ZD55 HUMAN TELOMERASE REVERSE TRANSCRIPTASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; GENE SILENCING; HUMAN; HUMAN CELL; NONHUMAN; NOTE; ONCOLYTIC VIROTHERAPY; RNA INTERFERENCE; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

EID: 66149139243     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.1.7422     Document Type: Note

References (20)

1. Davis JJ, Fang B. Oncolytic virotherapy for cancer treatment: challenges and solutions. J Gene Med 2005; 7:1380-1389 (Pubitemid 41672396)
2. Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 2008; 1785:217-231
3. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274:373-376 (Pubitemid 26353341)
4. Kirn D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Ther 2001; 1:525-538 (Pubitemid 33768667)
5. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 2006; 98:298-300.
6. Han ZQ, Assenberg M, Liu BL, et al. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy. J Gene Med 2007; 9:99-106. (Pubitemid 46444487)
7. Sauthoff H, Pipiya T, Heitner S, et al. Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein. Hum Gene Ther 2002; 13:1859-1871 (Pubitemid 35292681)
8. Dong F, Wang L, Davis JJ, et al. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus. Clin Cancer Res 2006; 12:5224-5230 (Pubitemid 44453352)
9. Lee YS, Kim JH, Choi KJ, et al. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res 2006; 12:5859-5868 (Pubitemid 44629619)
10. Choi KJ, Kim JH, Lee YS, et al. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther 2006; 13:1010-1020 (Pubitemid 43905854)
11. Zhao L, Gu J, Dong A, et al. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther 2005; 16:845-858 (Pubitemid 40982333)
12. Ren Z, Ye X, Fang C, et al. Intratumor injection of oncolytic adenovirus expressing HSP70 prolonged survival in melanoma B16 bearing mice by enhanced immune response. Cancer Biol Ther 2008; 7:191-195
13. Wang ZG, Zhao W, Ramachandra M, et al. An oncolytic adenovirus expressing soluble transforming growth factor-beta type II receptor for targeting breast cancer: in vitro evaluation. Mol Cancer Ther 2006; 5:367-373
14. Yoo JY, Kim JH, Kwon YG, et al. VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther 2007; 15:295-302. (Pubitemid 46111879)
15. Mokbel K. The evolving role of telomerase inhibitors in the treatment of cancer. Curr Med Res Opin 2003; 19:470-472 (Pubitemid 37122038)
16. Behlke MA. Progress towards in vivo use of siRNAs. Mol Ther 2006; 13:644-670
17. Kirn D. Armed interference: oncolytic viruses engineered to carry antitumor shRNAs. Mol Ther 2007; 15:227-228 (Pubitemid 46111870)
18. Zheng JN, Pei DS, Sun FH, et al. Inhibition of renal cancer cell growth by oncolytic adenovirus armed short hairpin RNA targeting hTERT gene. In this issue.
19. Massard C, Zermati Y, Pauleau AL, et al. hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway. Oncogene 2006; 25:4505-4514 (Pubitemid 44175110)
20. Cong Y, Shay JW. Actions of human telomerase beyond telomeres. Cell Res 2008; 18:725-732